People living with relapsed or refractory multiple myeloma now have a faster way to receive one of their key treatments. The FDA has approved a subcutaneous formulation of isatuximab‑irfc, marketed under the Sarclisa brand family, allowing the drug to be delivered as a quick under‑the‑skin injection rather than a lengthy intravenous infusion. The approval is backed by the Phase 3 IRAKLIA trial, which directly compared the subcutaneous route to the existing IV version, and the new formulation uses a wearable device called the CirCLIQ On‑Body Delivery System with a single‑dose vial. European regulators have moved in the same direction, with the CHMP adopting changes that enable the subcutaneous route for Sarclisa during its March 2026 meeting.
Why a Subcutaneous Sarclisa Option Changes the Treatment Calculus
Multiple myeloma is a blood cancer that typically requires repeated rounds of therapy over months or years. For patients on the IV version of isatuximab‑irfc, each infusion session means hours spent at a clinic or hospital, tethered to an IV line. The subcutaneous formulation cuts that chair time sharply because the drug is delivered through an on‑body injector rather than a drip. That distinction carries real weight for patients who are already managing fatigue, immune suppression, and the logistical burden of frequent medical visits.
The FDA decision on the subcutaneous injection covers the same combination regimen used in earlier trials: isatuximab‑irfc paired with pomalidomide and low‑dose dexamethasone. That regimen was first validated in the ICARIA‑MM study, a randomized, multicentre, open‑label, Phase 3 trial that demonstrated progression‑free survival gains when isatuximab was added to pomalidomide and dexamethasone compared to pomalidomide and dexamethasone alone. The subcutaneous version does not change the drug itself or the combination partners. It changes how the drug enters the body and, by extension, how much time patients spend receiving it.
For many patients, the switch from IV to subcutaneous administration could mean the difference between planning an entire day around treatment and fitting therapy into a more typical schedule. Shorter visits can reduce travel burden, time away from work or caregiving responsibilities, and exposure to healthcare settings where infections are a concern. The psychological effect of not being hooked up to an infusion line for hours should not be underestimated, especially for people who have already spent years in oncology clinics.
From a systems perspective, the subcutaneous option also changes how clinics allocate resources. Infusion chairs, nurses, and pharmacy preparation time are all finite. A formulation that can be delivered via an on‑body device, often in a fraction of the time required for an IV infusion, can free capacity for other complex treatments that have no alternative route. In centers where infusion backlogs are common, this may help shorten waitlists and improve throughput without adding physical space.
A reasonable question is whether this new delivery method will pull a meaningful share of eligible patients out of traditional infusion centers. One hypothesis holds that at least 30 percent of eligible U.S. patients could shift to the subcutaneous route within 18 months, a trend that would show up in Medicare claims data before any formal adherence study is published. That threshold is plausible given the convenience advantage, but several real‑world factors could slow adoption, including payer coverage decisions, clinic reimbursement structures, and provider familiarity with the on‑body injector device. Infusion centers generate revenue from chair time, and the financial incentives for clinics to keep patients on IV regimens are not trivial.
Patient preference will also play a role. Some individuals may feel more secure with the traditional IV setup, particularly if they associate it with prior successful responses. Others may worry about device malfunctions or skin reactions. Education around how the on‑body system works, what monitoring is required, and how adverse events are handled will shape uptake just as much as the raw clinical data.
IRAKLIA Trial Data and the CirCLIQ Device Behind the Approval
The regulatory case for the subcutaneous formulation rests on the IRAKLIA trial, registered as a Phase 3 study comparing subcutaneous isatuximab delivered via the on‑body injector against the standard IV formulation, both in combination with pomalidomide and dexamethasone, in patients with relapsed or refractory multiple myeloma. The study was designed to demonstrate that the subcutaneous route could match the IV version in drug exposure and safety, giving regulators the evidence needed to approve a new administration method for an already‑approved antibody.
IRAKLIA’s pharmacokinetic analyses focused on whether the subcutaneous formulation achieved comparable trough and peak concentrations to the IV infusion when used on the same dosing schedule. Non‑inferiority in exposure, combined with a similar safety profile, would support the conclusion that patients could expect equivalent clinical benefit. While progression‑free survival and response rates remain important, regulators were primarily looking for assurance that altering the route of administration did not reduce the amount of active drug reaching its target.
The device at the center of this shift is the CirCLIQ On‑Body Delivery System. According to the approved prescribing information, the subcutaneous injection is supplied in a single‑dose vial and administered using this wearable device, which comes with its own Instructions for Use. The label designates the product as Sarclisa Escena, distinguishing it from the original IV formulation. Patients or healthcare providers attach the device to the skin, and it delivers the drug over a programmed period, eliminating the need for IV access and the monitoring infrastructure that comes with it.
The CirCLIQ system is designed to standardize delivery while minimizing user steps. Once the vial is loaded and the device is applied, the injector controls the rate of administration, reducing the risk of rapid bolus injection or inconsistent technique. For clinics, this can translate into shorter hands‑on time per dose, although staff still need training on preparation, placement, and troubleshooting. For patients, the experience is closer to wearing a patch for a defined interval than undergoing a traditional infusion.
Safety considerations around the device include local injection‑site reactions, potential dislodgement, and rare mechanical failures. IRAKLIA and post‑marketing surveillance will be closely watched for any patterns of device‑related events that differ from those seen with IV administration. Early regulatory documents emphasize that hypersensitivity and infusion‑related reactions remain a concern with isatuximab itself, regardless of route, so observation periods and premedication strategies may persist even as administration time falls.
Building on ICARIA‑MM: Efficacy Foundations for Isatuximab
The clinical foundation for isatuximab‑irfc in this patient population traces back to the ICARIA‑MM trial, a randomized, multicentre, open‑label, Phase 3 study that evaluated isatuximab plus pomalidomide and low‑dose dexamethasone against pomalidomide and low‑dose dexamethasone alone in relapsed or refractory multiple myeloma. As reported in peer‑reviewed data, adding the anti‑CD38 antibody significantly improved progression‑free survival and deepened responses without introducing unexpected safety issues. Those results established the antibody‑based triplet as a standard option after at least two prior therapies.
ICARIA‑MM also clarified the toxicity profile that regulators and clinicians would later compare against the subcutaneous formulation. Infusion‑related reactions, cytopenias, and infections were prominent but generally manageable with standard supportive care. Because the mechanism of action and systemic exposure targets are the same for IV and subcutaneous isatuximab, IRAKLIA’s role was to confirm that shifting to an on‑body injector did not materially change this balance of benefit and risk.
In practice, the new formulation allows clinicians to offer the same evidence‑based regimen in a format better aligned with patient convenience. For individuals who responded well to IV isatuximab but struggled with the time commitment, switching to Sarclisa Escena could extend the feasibility of continuing therapy. For newly starting patients, the subcutaneous route may make it easier to accept a multi‑drug regimen that might otherwise feel overwhelming.
Looking ahead, real‑world data will determine how fully the promise of the subcutaneous option is realized. Adoption patterns across community and academic centers, differences in use between urban and rural settings, and payer policies on site‑of‑care will all shape the impact on patients’ daily lives. What is clear from the current regulatory and clinical record is that the core science of isatuximab‑based therapy remains intact; what is changing is the practical experience of receiving it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
